来曲唑在老年绝经后乳腺癌新辅助内分泌治疗中近期疗效观察.docVIP

来曲唑在老年绝经后乳腺癌新辅助内分泌治疗中近期疗效观察 　　[摘要]目的 探究来曲唑在老年绝经后乳腺癌新辅助内分泌治疗中的近期疗效。方法 选取2015年3月～2016年4月在我科接受治疗的30例50岁以上绝经后的乳腺癌患者作为研究对象，按病历号的不同分为两组，双号为观察组（n=15），单号为对照组（n=15），观察组患者给予来曲唑治疗，对照组患者给予三苯氧胺治疗，两组观察时间均为1年。1年后统计两组乳腺癌患者的治疗有效率及不良反应发生率。结果 观察组患者的治疗总有效率（66.67%）高于对照组（26.67%），差异有统计学意义（P0.05）。观察组患者的不良反应发生率（13.33%）低于对照组（53.33%），差异有统计学意义（P0.05）。结论 采用来曲唑治疗的乳腺癌患者，不良反应发生率较少，临床效果显著，值得在临床进行拓展。 　　[关键词]来曲唑；绝经后乳腺癌；新辅助内分泌 　　[中图分类号] R737.9 [文献标识码] A [文章编号] 1674-4721（2017）09（b）-0060-03 　　Short-term efficacy observation of Letrozole as a neoadjuvant endocrine therapy on postmenopausal breast cancer in the elderly 　　JIN Zhong-kui LIU Chang-shan XU Wang YU Kun-lin LUO Cai-lu 　　Department of Breast Thyroid Surgery，the People′s Hospital of Yichun City，Jiangxi Province，Yichun 336000，China 　　[Abstract]Objective To explore the short-term efficacy of Letrozole as a neoadjuvant endocrine therapy on postmenopausal breast cancer in the elderly.Methods From March 2015 to April 2016，30 patients with postmenopausal breast cancer who underwent treatment in our department were divided into two groups based on the different medical record number.Patients with the oven sequence were classified into the observation group （n=15），and the other was into the control group （n=15）.Letrozole was provided in the observation group and Tamoxifen was applied in the control group.The two groups were observed for one year.After one year，the effective therapeutic rate of breast cancer and the incidence of adverse reactions were calculated in both groups.Results The total effective therapeutic rate in the observation group （66.67%） was higher than the control group （26.67%），and the difference was statistically significant （P0.05）.The incidence of adverse reactions in the observation group （13.33%） was lower than that in the control group （53.33%），and the difference was statistically significant （P0.05）.Conclusion The application of Letrozole in patients with breast cancer has little incidence of adverse reactions and obtain